Q32 Bio Inc.

Clinical trials sponsored by Q32 Bio Inc., explained in plain language.

Q32 Bio Inc. QTTB NASDAQ

A clinical-stage biotech developing therapies for autoimmune and inflammatory diseases.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Not yet finished but already full! 1

New drug shows promise for regrowing hair in severe alopecia

Disease control Ongoing

This study tests a drug called bempikibart (ADX-914) in 75 adults with severe alopecia areata, a condition causing significant scalp hair loss. In the first part, some participants received the drug and some a placebo to see if it helps hair regrow. The second part gives the drug…

Phase 2 • Sponsor: Q32 Bio Inc. • Aim: Disease control

Last updated Jun 27, 2026 12:30 UTC

Q32 Bio Inc.

New drug shows promise for regrowing hair in severe alopecia